About Matridx
MatriDx Biotechnology Co., Ltd. is headquartered in Hangzhou, Zhejiang Province, China. Our mission is to deliver a total solution of in vitro molecular diagnostics for infectious diseases. We have utilized both CRISPR/Cas and Next-generation sequencing (NGS) technologies to develop a series of automated devices and reagents for pathogen detection. We are closely collaborating with medical facilities, CDCs, research organizations worldwide to establish automatic, fast and accurate molecular diagnostic platform incorporating big data and artificial intelligence.
Products and Services
SARS-CoV-2 nucleic acid detection kit (probe-based qRT-PCR)
For diagnosis of COVID-19 using upper and lower respiratory samples. TAT < 3 hours
Metagenomic next-generation sequencing (mNGS) total solution
For diagnosis of over 16000 DNA pathogens (bacteria, DNA viruses, fungi, parasites) and 200 RNA viruses (HIV, coronaviruses, Dengue viruses etc.) using a variety of clinical samples. TAT < 18 hours
Values:Innovative diagnostics for the future
Solution to microbial metagenomic Next-generation Sequencing (mNGS)
Product Overview
PDC-Seq™ - Potential Diagnostic Clue, is a convenient solution to carry out in-house metagenomic Next-generation sequencing. The product is designed by MatriDx Biotechnology Inc. It is comprised of microbial sonicator, automatic sequencing library preparation instrument (NGSmaster™), reagents and data analysis software. Using PDC-Seq™, lab personnel without specialized training could detect and analyze more than 16000 pathogens (bacteria, fungi, virus and parasites) and 2000 genes that confer antimicrobial resistance within 18 hours, directly from a variety of clinical sample types. Additionally, using reverse transcription-mediated virus enrichment technology (RT-VET), the RNA of SARS-CoV-2 can be efficiently enriched and sequenced in the same run, resulting in a genomic converge of up to 99.8%.
Product Features
Diagnose COVID-2019 from respiratory samples.
Enrich and obtain high coverage of SARS-CoV-2 genome.Diagnose
Co-infections in critically ill patient, for which precise treatment plan could be based on.
Easy to use with a TAT of less than 18 hours (illumina sequencer, SE75 20M reads).
Small instruments with minimal space requirement. Sample handling and library prep could be automatically achieved inside a Biosafety cabnet.
50 Tests (Cat#:MD028-P1)
250 Tests(Cat#:MD028-P2)
【Product description】
This kit is used to detect the presence of SARS-CoV-2 viral RNA in samples collected from Upper respiratory (nasopharyngeal swab, sputum) and Lower respiratory tract (bronchoalveolar lavage fluid). The testing result can be used to aid clinical diagnosis of COVID-19.
【Test performance】
(1)Limit of detection:1x10³ viral copies/mL。
(2)Precision:coefficient of variation (CV)≤10% when performed on the same reference sample for 10 times.
(3)Reproducibility: when performed six times on the positive control using two technical replicates for each experiment, both ORF1ab and N gene showed positive results. When performed two times on the negative control using two technical replicates for each experiment,both ORF1ab and N gene showed negative results.
【Testing method】
This kit uses one-step reverse transcriptase-polymerase chain reaction (one-step RT-PCR) by designing primers and Taqman probes (FAM-tag)
【Recommend thermocycler】
This kit is suitable for ABI 7900HT, ABI 7300, ABI StepOnePlus™, ABI 7500, ABI 7500 Fast, Stratagene Mx3000P, Roche, Bio-Ra
【Sample types】
Upper respiratory samples (nasopharyngeal swab, sputum)
Lower respiratory samples (bronchoalveolar lavage fluid)
【Sample storage】
Testing is recommended immediately following sample collection. Samples can be stored at 4℃ for a maximum of 24 hours. For long-term storage, -80±5℃ is recommended and repeated freeze-and-thaw should be avoided.
Hangzhou Matridx Biotechnology.,Ltd.
Add.:Db 4,2073 JinChang Rd,Hangzhou,Zhejiang Province,China 310005
Tel : 400 0888 022
Official WeChat @Matridx
Official Weibo @Matridx